SuperGen earns $20 million Dacogen injection milestone

By Elaine Rigoli

Tampa, Fla., May 26 - SuperGen, Inc. announced that the first commercial shipment of Dacogen (decitabine) injection was released by MGI Pharma, Inc. to wholesale drug-distributors earlier this week.

Under the terms of its exclusive worldwide licensing agreement with MGI Pharma, SuperGen said it has achieved the $20 million commercialization milestone.

Additionally, SuperGen will earn a royalty on worldwide net sales starting at 20% and escalating to a maximum of 30%.

MGI Pharma, based in Bloomington, Minn., is an oncology and acute-care focused biopharmaceutical company.

SuperGen is a pharmaceutical company based in Dublin, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.